Möchten Sie immer auf dem neuesten Stand bleiben?

DANBURY, Conn., June 19, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) today announced the pricing of an underwritten public offering of 4,482,760 shares of its common stock at a public offering...

DANBURY, Conn., June 18, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) today announced that it is offering to sell, subject to market and other conditions, shares of its common stock in an...

- Selected by ADA for late breaking presentation of Biodel's proprietary ultra-rapid-acting analog formulations - Presentation of data for new class of concentrated ultra-rapid-acting...

- New Drug Application submission anticipated in 2015 - Acquired worldwide exclusivity to proprietary dual-chamber device DANBURY, Conn., June 6, 2013 (GLOBE NEWSWIRE) -- Biodel Inc....

DANBURY, Conn., May 8, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) today reported financial results for the second fiscal quarter ended March 31, 2013. Portfolio highlights since last fiscal...

DANBURY, Conn., May 6, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) will issue its second quarter fiscal year 2013 financial results on May 8, 2013. Following the release of the company's...

DANBURY, Conn., March 28, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) today announced the completion of patient enrollment in a Phase 2 clinical study of ultra-rapid-acting prandial insulin...

DANBURY, Conn., Feb. 12, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) today reported financial results for the first fiscal quarter ended December 31, 2012. Highlights since first fiscal...

DANBURY, Conn., Feb. 6, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) will issue its first quarter fiscal year 2013 financial results on February 12, 2013. Following the release of the company's...

DANBURY, Conn., Feb. 5, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) announced today that management will be presenting an overview of the company's technologies, development programs, and...